MARKER THERAPEUTICS
Marker Therapeutics is a clinical stage immuno-oncology company focused on developing adoptive non-gene modified T cell therapies for the treatment of hematologic malignancies such as Acute Myeloid Leukemia, Lymphoma, and Multiple Myeloma. Marker’s MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Marker’s therapies is significantly reduced.
MARKER THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
1992-01-01
Address:
Minneapolis, Minnesota, United States
Country:
United States
Website Url:
http://www.markertherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(713) 400-6400
Email Addresses:
[email protected]
Total Funding:
69.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Feldan Therapeutics
Feldan Therapeutics has developed a patented peptide-based technology platform.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-05-15 | TapImmune | TapImmune acquired by Marker Therapeutics | N/A |
Investors List
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - Marker Therapeutics
Official Site Inspections
http://www.markertherapeutics.com Semrush global rank: 8.02 M Semrush visits lastest month: 388
- Host name: hwsrv-245137.hostwindsdns.com
- IP address: 23.254.209.175
- Location: Seattle United States
- Latitude: 47.4902
- Longitude: -122.3004
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98168
More informations about "Marker Therapeutics"
Marker Therapeutics, Inc.
Harnessing millions of years of immunologic evolution, Marker’s Multi-Antigen Recognizing (MAR) T cell therapy is designed to recognize and kill highly heterogeneous tumors without the need …See details»
Our Company - Marker Therapeutics, Inc.
Marker Therapeutics is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood cancers and solid tumors.See details»
Corporate Profile - Marker Therapeutics, Inc.
We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based …See details»
Board of Directors - Marker Therapeutics, Inc.
John R. Wilson is Managing Director of ViraCyte, LLC, and the CEO of Wilson Wolf Manufacturing. Mr. Wilson has over 30 years of experience in the design, development and manufacture of products for the field of biotechnology, …See details»
Marker Therapeutics - Crunchbase Company …
Marker Therapeutics is a clinical stage immuno-oncology company focused on developing adoptive non-gene modified T cell therapies for the treatment of hematologic malignancies such as Acute Myeloid Leukemia, Lymphoma, and …See details»
Marker Therapeutics, Inc. | LinkedIn
Marker Therapeutics, Inc. | 4,081 followers on LinkedIn. Pioneering a Multi-Antigen Approach | We are a clinical-stage immuno-oncology company specializing in the development of next-generation...See details»
Marker Therapeutics Announces Clinical Program Updates …
Jan 8, 2024 · Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma. MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical …See details»
Marker Therapeutics Announces Clinical Program Updates …
HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T …See details»
Marker Therapeutics Receives Approval from United States …
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell …See details»
Marker Therapeutics Reports Year-End 2023 Corporate …
HOUSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T …See details»
Marker Therapeutics Receives Approval from United States …
Jan 22, 2024 · Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the …See details»
Marker Therapeutics Announces Clinical Program Updates …
HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell …See details»
Marker Therapeutics, Inc. (MRKR) - Stock Analysis
5 days ago · Get a real-time Marker Therapeutics, Inc. (MRKR) stock price quote with breaking news, financials, statistics, charts and more.See details»
Manufacturing - Marker Therapeutics, Inc.
Marker isolates and cultures the immune cells with a proprietary blend of tumor-associated antigens, cytokines and antigen presenting cells. Marker is able to isolate, activate and expand …See details»
Press Releases - Marker Therapeutics, Inc.
Nov 14, 2024 · The Investor Relations website contains information about Marker Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Marker Therapeutics Announces Sustained Complete …
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell …See details»
Marker Therapeutics Announces FDA Clearance of IND for …
HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation …See details»
Marker Therapeutics Announces Clinical Program Updates …
Feb 16, 2022 · Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the …See details»
Marker Therapeutics, Inc. (MRKR) - Yahoo Finance
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment …See details»
Marker Therapeutics to Present at Three Upcoming …
HOUSTON, Sept. 7, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T …See details»